| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Charles River Laboratories International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4,048.97 |
| 52 Week High | US$4,073.04 |
| 52 Week Low | US$3,249.12 |
| Beta | 1.41 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -3.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRL * | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how CRL * performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how CRL * performed against the MX Market.
Price Volatility
| CRL * volatility | |
|---|---|
| CRL * Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: CRL * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CRL *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 21,100 | Jim Foster | www.criver.com |
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
Charles River Laboratories International, Inc. Fundamentals Summary
| CRL * fundamental statistics | |
|---|---|
| Market cap | Mex$203.45b |
| Earnings (TTM) | Mex$8.05b |
| Revenue (TTM) | Mex$70.08b |
25.3x
P/E Ratio2.9x
P/S RatioIs CRL * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRL * income statement (TTM) | |
|---|---|
| Revenue | US$4.13b |
| Cost of Revenue | US$2.60b |
| Gross Profit | US$1.53b |
| Other Expenses | US$1.05b |
| Earnings | US$474.62m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 9.24 |
| Gross Margin | 37.03% |
| Net Profit Margin | 11.49% |
| Debt/Equity Ratio | 71.7% |
How did CRL * perform over the long term?
See historical performance and comparison